Federal Trade Commission. (12/16/19). "Press Release: Federal Trade Commission Closes Investigation of Roche Holding AG’s Proposed Acquisition of Spark Therapeutics, Inc.".

	Region	United States (USA)
	Organisation	Spark Therapeutics Inc.
	Group	Roche (Group)
	Product	gene therapy hemophilia A
	Product 2	Hemlibra®
	Index term	Spark Therapeutics–Roche: investment, 201902–201912 acquisition $4.3b cash tender offer for all shares at $114.5/share

The Federal Trade Commission has closed its investigation into Roche Holding AG’s proposed acquisition of Spark Therapeutics, Inc.

According to a Commission Statement, after an exhaustive, 10-month investigation into whether the merger would lessen potential competition in the U.S. market for hemophilia A therapies, the evidence “did not indicate that Roche would have the incentive to delay or terminate Spark’s developmental effort for its hemophilia A gene therapy, or that the acquisition would affect Roche’s incentives regarding [its hemophilia treatment drug] Hemlibra.”

The Commission vote to close the investigation was 5-0.

The Federal Trade Commission works to promote competition, and protect and educate consumers. You can learn more about how competition benefits consumers or file an antitrust complaint. Like the FTC on Facebook, follow us on Twitter, read our blogs, and subscribe to press releases for the latest FTC news and resources.

Contact Information

MEDIA CONTACT:
Betsy Lordan
Office of Public Affairs
202-326-3707

Record changed: 2023-06-05